Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan;1(1):41-7.
doi: 10.1177/1941875210386491.

Neuroleptic malignant syndrome: a review for neurohospitalists

Brian D Berman  1
Affiliations

Neuroleptic malignant syndrome: a review for neurohospitalists

Brian D Berman. Neurohospitalist. 2011 Jan.

Abstract

Neuroleptic malignant syndrome (NMS) is a life-threatening idiosyncratic reaction to antipsychotic drugs characterized by fever, altered mental status, muscle rigidity, and autonomic dysfunction. It has been associated with virtually all neuroleptics, including newer atypical antipsychotics, as well as a variety of other medications that affect central dopaminergic neurotransmission. Although uncommon, NMS remains a critical consideration in the differential diagnosis of patients presenting with fever and mental status changes because it requires prompt recognition to prevent significant morbidity and death. Treatment includes immediately stopping the offending agent and implementing supportive measures, as well as pharmacological interventions in more severe cases. Maintaining vigilant awareness of the clinical features of NMS to diagnose and treat the disorder early, however, remains the most important strategy by which physicians can keep mortality rates low and improve patient outcomes.

Keywords: movement disorders; neurohospitalist; neuroleptic malignant syndrome.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interests with respect to the authorship and/or publication of this article.

References

    1. Ayd F. Fatal hyperpyrexia during chlorpromazine therapy. J Clin Exp Psychopathol. 1956;17(2):189–192 - PubMed
    1. Delay J, Pichot P, Lemperiere T. A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses (in French). Ann Med Psychol (Paris). 1960;118(1):145–152 - PubMed
    1. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv. 1998;49(9):1163–1172 - PubMed
    1. Stubner S, Rustenbeck E, Grohmann R, et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry. 2004;37(1):S54–S64 - PubMed
    1. Pope HG, Keck PE, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric-hospital. Am J Psychiatry. 1986;143(10):1227–1233 - PubMed